icon-folder.gif   Conference Reports for NATAP  
 
  EASL 45th Annual Meeting
April 14-18, 2010
Vienna, Austria
Back grey_arrow_rt.gif
 
 
 
Pegasys vs Pegintron, Baseline characteristics and on-treatment predictors of responses from real-world patient cohorts: interim results of the multinational PROPHESYS cohorts
 
 
  Reported by Jules Levin
45th Annual Meeting of the European
Association for the Study of the Liver (EASL), April 14-18, 2010, Vienna, Austria
 
P. Ferenci,1 M.L. Shiffman,2 M. Puoti,3 A. Orlandini,4 F.A. Caruntu,5 D. Ouzan,6 M. Bozic,7 M. Bourliere,8 G.F. Silva,9 J. Schuller,10 J-P. Mulkay,11 A. Horban,12 D. Messinger,13 A. Tietz,14 A. Mangia15 1Medical University of Vienna, Vienna, Austria; 2 Liver Institute of Virginia, Bon Secours Health System, Newport News, VA, USA; 3University of Brescia, Brescia, Italy; 4Unit of Infectious Diseases and Hepatology, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy; 5Matei Bals Infectious Diseases Institute, Bucharest, Romania; 6Institut Arnault Tzanck, Saint-Laurent-du-Var, France; 7Clinical Center of Serbia, Beograd, Serbia; 8Hospital Saint Joseph, Marseille, France; 9Botucatu School of Medicine, Botucatu, Brazil; 10Szent Laszlo Hospital, Budapest, Hungary; 11H˘pital Saint Pierre, Bruxelles, Belgium; 12Medical University Clinic ooInfectious Diseases, Warsaw, Poland; 13IST GmbH, Mannheim, Germany; 14Roche, Basel, Switzerland; 15Hospital Casa Sollievo della Sofferenza, Rotondo, Italy This research was funded by Roche, Basel, Switzerland
 
"Analysis of baseline factors in HCV genotype 1 or 4 patients showed the following predictors to be significantly associated with viral clearance by week 12 (RVR or cEVR) by MLR: prescription of peginterferon alfa-2a (40KD) [vs Pegintron alfa-2b] (p<0.0001), lower HCV RNA level (p<0.0001), Asian vs Caucasian race (p=0.0490), Caucasian vs Black race (p=0.0057), Caucasian vs other race (p=0.0408), higher platelets (p<0.0001), absence of cirrhosis vs cirrhosis (p<0.0001), histology not assessed vs cirrhosis (p=0.0002), ALT quotient >3.0 (p=0.0004), younger age (p<0.0001) and lower body mass index (BMI) (p=0.0213) (Figure 3 below)."

All patients recorded as Asian were enrolled at sites in Europe, North and South America and North Africa
Genotype 1 and 4 patients without a histological diagnosis (i.e. not assessed) were typically more similar to patients with a confirmed diagnosis of no cirrhosis in terms of baseline age, diagnosis of steatosis, ALT ratio and platelet count ALT = alanine aminotransferase

Figure 3. Significant predictors of viral clearance (RVR/cEVR) in genotype 1 or 4 patients

Figure 4. Significant predictors of viral clearance (RVR/cEVR) in genotype 2 or 3 patients